Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

Pancreatic ductal adenocarcinoma (PDAC), which is the most common form of pancreatic cancer, is an aggressive disease with a poor prognosis, making it the most lethal tumor. The overall 5-year survival rate of PDAC is around 10  % despite the advances made in recent years in the field of oncology [1,2]. The only curative option for patients with this oncological condition is surgical resection of the primary tumor, although this is only feasible in a small percentage of cases when the malignancy is detected at a very ear ly stage.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research